Observational studyCancer medicine2026

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.

Debu Tripathy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.